Assess the data and tweets to estimate whether the closing price of $amgn will escalate or deflate at 2017-07-27. Respond with either Rise or Fall.
Context: date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2017-07-13,-1.0,0.7,-1.1,1.0,1.0,-1.1,-1.2,-1.2,-2.2,-3.0,-4.0
2017-07-14,-1.0,0.3,-1.5,1.2,1.2,-1.7,-2.1,-2.3,-3.0,-3.8,-4.7
2017-07-17,-0.3,0.8,-0.4,0.2,0.2,-1.2,-2.0,-2.2,-2.7,-3.7,-4.5
2017-07-18,-0.5,0.1,-0.8,0.0,0.0,-0.8,-1.8,-2.1,-2.4,-3.4,-4.3
2017-07-19,-0.6,0.0,-1.5,1.0,1.0,-1.1,-2.4,-2.7,-3.0,-4.0,-4.8
2017-07-20,-0.2,0.8,-0.2,0.1,0.1,-0.7,-2.1,-2.6,-2.8,-3.8,-4.6
2017-07-21,-0.5,0.2,-0.6,0.5,0.5,-0.8,-2.1,-2.8,-3.1,-3.9,-4.7
2017-07-24,-0.5,0.2,-1.3,0.5,0.5,-0.9,-2.1,-2.9,-3.4,-3.9,-4.8
2017-07-25,0.6,0.9,-0.3,-0.1,-0.1,-0.4,-1.5,-2.6,-3.1,-3.5,-4.4
2017-07-26,0.1,1.7,-0.4,-2.8,-2.8,2.0,1.4,0.3,-0.2,-0.5,-1.5

2017-07-13: $amgn max pain is 172.50 for maturity 07/14/2017. prev close = 173.27.   |rt AT_USER $ibb $amgn $celg $gild break out. |$amgn gap fill special, if they stay w/ biotech this name needs to be on your ra
2017-07-14: rt AT_USER amgen receives fda approval for blincyto  $mrk $amgn |s&amp;p100 #stocks performance $gd $amgn $msft $nee $rtn $bmy $celg $cat $fdx $jnj $pcln $mdt $dis $agn $intc  more@ |can $imgn's lead 
2017-07-15: rt AT_USER "all incentives have a way of failing, just look at our society" #scotus justice sotomayor at sandoz v. amgen. #biosimi¡­|$amgn max pain is 165.00 for maturity 07/21/2017. prev close = 177.
2017-07-16: rt AT_USER $amgn says AT_USER gave a crl for osteoporosis drug candidate romosozumab, will supply data from two trials|rt AT_USER $amgn says AT_USER gave a crl for osteoporosis drug candidate romosozu
2017-07-17: fda issues a crl for $amgn's evenity |amgen fda letter isn¡¯t a surprise (or a concern), says jefferies - barron's $amgn |commented on spectrum pharmaceuticals: will rolontis substantially increase pr
2017-07-18: what would the web address be? $mnkd or $amgn or ???  maybe it's not there for a reason. |oppenheimer holdings, inc. reaffirms ¡°outperform¡± rating for amgen inc. $amgn |$amgn gap filled, earnings so
2017-07-19: rt AT_USER $trow $amgn $dhil $hls  - new investment opportunities from william, what are your thoughts? |$trow $amgn $dhil $hls  - new investment opportunities from william, what are your thoughts? |c
2017-07-20: amgen inc. $amgn shares sold by sheaff brock investment advisors llc |market commentary for friday, july 21 - $msft, $psx, $amgn, $dds, $chkp, $bp, $isrg, $wmt, $aapl, $skx, $xrt  |rt AT_USER aimovig 
2017-07-21: fda accepts #amgen's biologics license application for aimovig. read more:  $amgn|rt AT_USER $amgn monthly rsi breaking downtrend as looks to leave 40 point range trade |#fda accepted reviewing $amgn¡
2017-07-22: $amgn high open interest range is 157.50 to 177.50 for option expiration 07/28/2017.  |rt AT_USER this great earnings #infographic from AT_USER helps prep u 4 the week ahead $mcd $mmm $goog $gm $amzn 
2017-07-23: $nvs $amgn are amongst #stocks downgraded today! read our daily #fundamentalanalysis report here &gt;&gt;&gt;&gt;¡­ |$nvs $amgn are amongst #stocks downgraded today! read our daily #fundamentalanalysi
2017-07-24: {video} biotech analysis + trade ideas: $ibb $xbi $gild $celg $amgn $agn #options --&gt;  |s&amp;p100 #stocks performance $gd $amgn $msft $nee $rtn $bmy $celg $cat $fdx $jnj $pcln $mdt $dis $agn $intc
2017-07-25: $amgn amgen option order flow sentiment is 77.3% bullish. |rt AT_USER $amgn 2q17 revenue of $5.8bn and eps of $3.27 beat consensus of $5.67bn and $3.11 but stock's down 1.9% after hours.|we calculated
2017-07-26: $amgn sum put vol=4,515 sum call vol=10,282 putcallratio=0.44 expiration 07/28/2017 .  |amgen and novartis: first mover advantage is a must  $amgn $nvs |AT_USER AT_USER beginning of patent cliff/pipel
Answer:
Assess the data and tweets to estimate whether the closing price of $amgn will escalate or deflate at 2017-07-27. Respond with either Rise or Fall.
Context: date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2017-07-13,-1.0,0.7,-1.1,1.0,1.0,-1.1,-1.2,-1.2,-2.2,-3.0,-4.0
2017-07-14,-1.0,0.3,-1.5,1.2,1.2,-1.7,-2.1,-2.3,-3.0,-3.8,-4.7
2017-07-17,-0.3,0.8,-0.4,0.2,0.2,-1.2,-2.0,-2.2,-2.7,-3.7,-4.5
2017-07-18,-0.5,0.1,-0.8,0.0,0.0,-0.8,-1.8,-2.1,-2.4,-3.4,-4.3
2017-07-19,-0.6,0.0,-1.5,1.0,1.0,-1.1,-2.4,-2.7,-3.0,-4.0,-4.8
2017-07-20,-0.2,0.8,-0.2,0.1,0.1,-0.7,-2.1,-2.6,-2.8,-3.8,-4.6
2017-07-21,-0.5,0.2,-0.6,0.5,0.5,-0.8,-2.1,-2.8,-3.1,-3.9,-4.7
2017-07-24,-0.5,0.2,-1.3,0.5,0.5,-0.9,-2.1,-2.9,-3.4,-3.9,-4.8
2017-07-25,0.6,0.9,-0.3,-0.1,-0.1,-0.4,-1.5,-2.6,-3.1,-3.5,-4.4
2017-07-26,0.1,1.7,-0.4,-2.8,-2.8,2.0,1.4,0.3,-0.2,-0.5,-1.5

2017-07-13: $amgn max pain is 172.50 for maturity 07/14/2017. prev close = 173.27.   |rt AT_USER $ibb $amgn $celg $gild break out. |$amgn gap fill special, if they stay w/ biotech this name needs to be on your ra
2017-07-14: rt AT_USER amgen receives fda approval for blincyto  $mrk $amgn |s&amp;p100 #stocks performance $gd $amgn $msft $nee $rtn $bmy $celg $cat $fdx $jnj $pcln $mdt $dis $agn $intc  more@ |can $imgn's lead 
2017-07-15: rt AT_USER "all incentives have a way of failing, just look at our society" #scotus justice sotomayor at sandoz v. amgen. #biosimi¡­|$amgn max pain is 165.00 for maturity 07/21/2017. prev close = 177.
2017-07-16: rt AT_USER $amgn says AT_USER gave a crl for osteoporosis drug candidate romosozumab, will supply data from two trials|rt AT_USER $amgn says AT_USER gave a crl for osteoporosis drug candidate romosozu
2017-07-17: fda issues a crl for $amgn's evenity |amgen fda letter isn¡¯t a surprise (or a concern), says jefferies - barron's $amgn |commented on spectrum pharmaceuticals: will rolontis substantially increase pr
2017-07-18: what would the web address be? $mnkd or $amgn or ???  maybe it's not there for a reason. |oppenheimer holdings, inc. reaffirms ¡°outperform¡± rating for amgen inc. $amgn |$amgn gap filled, earnings so
2017-07-19: rt AT_USER $trow $amgn $dhil $hls  - new investment opportunities from william, what are your thoughts? |$trow $amgn $dhil $hls  - new investment opportunities from william, what are your thoughts? |c
2017-07-20: amgen inc. $amgn shares sold by sheaff brock investment advisors llc |market commentary for friday, july 21 - $msft, $psx, $amgn, $dds, $chkp, $bp, $isrg, $wmt, $aapl, $skx, $xrt  |rt AT_USER aimovig 
2017-07-21: fda accepts #amgen's biologics license application for aimovig. read more:  $amgn|rt AT_USER $amgn monthly rsi breaking downtrend as looks to leave 40 point range trade |#fda accepted reviewing $amgn¡
2017-07-22: $amgn high open interest range is 157.50 to 177.50 for option expiration 07/28/2017.  |rt AT_USER this great earnings #infographic from AT_USER helps prep u 4 the week ahead $mcd $mmm $goog $gm $amzn 
2017-07-23: $nvs $amgn are amongst #stocks downgraded today! read our daily #fundamentalanalysis report here &gt;&gt;&gt;&gt;¡­ |$nvs $amgn are amongst #stocks downgraded today! read our daily #fundamentalanalysi
2017-07-24: {video} biotech analysis + trade ideas: $ibb $xbi $gild $celg $amgn $agn #options --&gt;  |s&amp;p100 #stocks performance $gd $amgn $msft $nee $rtn $bmy $celg $cat $fdx $jnj $pcln $mdt $dis $agn $intc
2017-07-25: $amgn amgen option order flow sentiment is 77.3% bullish. |rt AT_USER $amgn 2q17 revenue of $5.8bn and eps of $3.27 beat consensus of $5.67bn and $3.11 but stock's down 1.9% after hours.|we calculated
2017-07-26: $amgn sum put vol=4,515 sum call vol=10,282 putcallratio=0.44 expiration 07/28/2017 .  |amgen and novartis: first mover advantage is a must  $amgn $nvs |AT_USER AT_USER beginning of patent cliff/pipel
Answer:+Fall